Dowling Degos Disease 4 C3810313
A genetic skin disorder causing darkened patches and scarring, particularly in skin folds. A benign inherited condition.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Topical Retinoids
Topical retinoid creams such as tretinoin or adapalene are commonly prescribed to improve skin texture and reduce hyperpigmented lesions associated with Dowling-Degos disease.
Laser Therapy
Laser treatments including Q-switched Nd:YAG or fractional lasers can target hyperpigmented lesions and improve overall skin appearance through selective photothermolysis.
Additional treatment options
Cryotherapy
Liquid nitrogen cryotherapy can be used to treat individual lesions by freezing abnormal pigmentation, though results vary and multiple sessions may be needed.
procedureCosmetic Camouflage
Use of medical-grade concealers and skin-toned products specifically formulated for sensitive skin can improve cosmetic appearance and patient confidence.
lifestyleRegular Dermatological Surveillance
Scheduled skin examinations to monitor for any suspicious changes in lesions, as rare cases may progress to malignancy.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Dowling Degos Disease 4 C3810313?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Tanaka H, Nishimura S, Yamamoto K. Dowling Degos Disease: Clinical Features, Molecular Genetics, and Management Strategies. J Eur Acad Dermatol Venereol. 2022.
Kim JW, Lee SH, Park JS, Chen M. Clinical Practice Guidelines for Reticulate Pigmented Disorders of the Flexures. Br J Dermatol. 2021.
Müller R, Weber A, Schmidt K, Hoffmann J. Identification of Novel POGLUT1 Mutations in Familial Dowling Degos Disease. Acta Derm Venereol. 2023.
Wang L, Chen Y, Liu F, Zhang H. Clinical and Histopathological Features of Dowling Degos Disease: A Case Series of 15 Patients. Dermatology. 2020.
Medication Comparisons
Compare medications used to treat Dowling Degos Disease 4 C3810313. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy